A Long-Term View of Cardiovascular Risk After Cancer Treatment
Stephanie Dixon, MD, MPH
Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Jonathon Cohen, MD, MS
Reducing Cardiovascular Risk in Adult Survivors of Childhood Cancer
Supportive Care Before CLL Treatment: Infection Risk and Comorbidity Management
Kerry A. Rogers, MD
How Myeloid Mutations in ALL Inform Treatment Decisions
Caner Saygin, MD
Supportive Care During and After CLL Treatment: What to Prioritize
Making the Most of WCLC 2026: A Guide for Early-Career Professionals
Triparna Sen, PhD
Closing Gaps in CRC Screening: From Stool-Based Testing to Timely Colonoscopy
Shelina Ramnarine, PhD
David A. Johnson, MD, FACG, FACP
Closing the Colonoscopy Follow-Up Gap: Insights from a JNCCN Study
Peter Buch, MD, FACG, AGAF, FACP
Mallik Greene, PhD
Jordan Karlitz, MD
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Virginia Kaklamani, MD, DSc
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Saad Z. Usmani, MD, MBA
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.